Abstract #132: A Phase 1 Dose Escalation Study of IGM-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies

The 63rd ASH Annual Meeting and Exposition – December 11-14, 2021

Elizabeth Budde, MD PhD, Ajay K. Gopal, MD, Won Seog Kim, MD PhD, Ian Flinn, MD PhD, Chan Y. Cheah, MBBS, Loretta Nastoupil, MD, Matthew Matasar, MD, Catherine Diefenbach, MD, Gareth P. Gregory, MBBS PhD, Ibrahim Qazi, PharmD, Ching-Fai Pang, PhD, Maya Leabman, PhD, Genevive Hernandez, PhD, Iris Sison, Bruce Keyt, PhD, Daniel Chen, MD PhD, and Philippe Armand, MD PhD

ASH Abstract #132 – IGM-2323

Posted in publications.